

# Glycerophosphocholine Utilization by *Candida albicans*

## ROLE OF THE *Git3* TRANSPORTER IN VIRULENCE\*

Received for publication, July 26, 2013, and in revised form, October 10, 2013. Published, JBC Papers in Press, October 10, 2013, DOI 10.1074/jbc.M113.505735

Andrew C. Bishop<sup>‡</sup>, Shantanu Ganguly<sup>§</sup>, Norma V. Solis<sup>¶</sup>, Benjamin M. Cooley<sup>‡</sup>, Michael I. Jensen-Seaman<sup>‡</sup>, Scott G. Filler<sup>¶</sup>, Aaron P. Mitchell<sup>§</sup>, and Jana Patton-Vogt<sup>‡</sup><sup>1</sup>

From the <sup>‡</sup>Department of Biological Sciences, Duquesne University, Pittsburgh, Pennsylvania 15282, the <sup>§</sup>Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, the <sup>¶</sup>Division of Infectious Disease, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California 90502, and the <sup>||</sup>David Geffen School of Medicine at UCLA, Los Angeles, California 90024

**Background:** Glycerophosphocholine (GroPCho) is a phospholipid metabolite found throughout the human body.

**Results:** Loss of *Git3* and *Git4* in *C. albicans* abolishes GroPCho transport, and *Git3*-deficient cells exhibit reduced virulence.

**Conclusion:** The major GroPCho transporter, *Git3*, is required for full virulence.

**Significance:** This report is the first to identify a eukaryotic GroPCho-specific transporter and the first to implicate GroPCho utilization in pathogenicity.

*Candida albicans* contains four ORFs (*GIT1,2,3,4*) predicted to encode proteins involved in the transport of glycerophosphodiester metabolites. Previously, we reported that *Git1*, encoded by ORF 19.34, is responsible for the transport of intact glycerophosphoinositol but not glycerophosphocholine (GroPCho). Here, we report that a strain lacking both *GIT3* (ORF 19.1979) and *GIT4* (ORF 19.1980) is unable to transport [<sup>3</sup>H]GroPCho into the cell. In the absence of a GroPCho transporter, *C. albicans* can utilize GroPCho via a mechanism involving extracellular hydrolysis. Upon reintegration of either *GIT3* or *GIT4* into the genome, measurable uptake of [<sup>3</sup>H]GroPCho is observed. Transport assays and kinetic analyses indicate that *Git3* has the greater transport velocity. We present evidence that *GDE1* (ORF 19.3936) codes for an enzyme with glycerophosphodiesterase activity against GroPCho. Homozygous deletion of *GDE1* results in a buildup of internal GroPCho that is restored to wild type levels by reintegration of *GDE1* into the genome. The transcriptional regulator, *Pho4*, is shown to regulate the expression of *GIT3*, *GIT4*, and *GDE1*. Finally, *Git3* is shown to be required for full virulence in a mouse model of disseminated candidiasis, and *Git3* sequence orthologs are present in other pathogenic *Candida* species. In summary, we have characterized multiple aspects of GroPCho utilization by *C. albicans* and have demonstrated that GroPCho transport plays a key role in the growth of the organism in the host.

*Candida albicans* is an opportunistic fungal pathogen that is part of the natural flora of healthy human beings (1). *C. albicans* together with other *Candida* species account for most hospital-related fungal infections. Patients in the intensive care unit, individuals with compromised immune systems, and patients

undergoing cancer treatments or immunosuppressant therapy are most likely to develop invasive candidal infection (2, 3). Opportunistic pathogens such as *C. albicans* develop strategies to survive and proliferate in the various niches of the host. This survival must depend upon the ability of the organism to efficiently utilize the available nutrients. Indeed, comparative analysis of the genome of the nonpathogenic *Saccharomyces cerevisiae* with that of *C. albicans* has uncovered numerous metabolic differences, including the expansion of gene families related to energy production, nutrient transport, and extracellular hydrolytic activity (4, 5). Secreted phospholipase activity, for example, is prevalent in pathogenic fungi and has been linked to pathogenicity (6, 7). It has been postulated that phospholipases enhance virulence by damaging host membranes and enabling penetration by the organism (6), but their importance may also be related to their ability to release phospholipid metabolites that can be used as nutrients.

Phospholipases of the B type (PLBs)<sup>2</sup> deacylate glycerophospholipids (Fig. 10C) to produce fatty acids and water-soluble metabolites called glycerophosphodiesters (GroPXs) (6, 8). Two such GroPXs are glycerophosphoinositol (GroPIIns) and glycerophosphocholine (GroPCho) produced through the deacylation of phosphatidylinositol and phosphatidylcholine (PC), respectively. *C. albicans* contains five PLB-encoding genes (7), and loss of *PLB1* or *PLB5* has been shown to attenuate virulence (9, 10). In addition to the GroPXs potentially produced through fungus-related phospholipases, GroPXs are found throughout mammalian tissues and fluids as a result of host-specific phospholipases, which can include phospholipases of the A<sub>1</sub> and A<sub>2</sub> type, as well as PLBs (11–20). GroPCho and its precursor, PC, are present in serum (14, 15). They are also found in the gastrointestinal tract and the urinary tract (11,

\* This work was supported, in whole or in part, by National Institutes of Health Grants R15GM104876 (to J. P.-V.), R01AI070272 (to A. P. M.), and R01AI054928 (to S. G. F.). This work was also supported by National Science Foundation Grant BCS-0922525 (to M. J. S.).

<sup>1</sup> To whom correspondence should be addressed: Dept. of Biological Sciences, Duquesne University, Pittsburgh, PA 15282. Tel.: 412-396-1053; Fax: 412-396-5907; E-mail: pattonvogt@duq.edu.

<sup>2</sup> The abbreviations used are: PLB, phospholipase B; GroPX, glycerophosphodiester; GroPCho, glycerophosphocholine; GroPIIns, glycerophosphoinositol; GroP, glycerol 3-phosphate; PC, phosphatidylcholine; nt, nucleotide; YNB, yeast nitrogen base; qPCR, quantitative PCR; XTT, 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide; DI, deionized; ODU, optical density unit.

**TABLE 1**  
Strains used in the study

BWP17	<i>ura3Δ::λimm434 his1::hisG arg4::hisG</i>	26
WT (DAY185)	<i>ura3Δ::λimm434 his1::hisG arg4::hisG</i>	25, 58
WT-TF	<i>ura3Δ::λimm434 ARG4::URA3::arg4::hisG HIS1::his1::hisG</i>	59
<i>pho4Δ/Δ</i>	<i>arg4Δ LEU2 HIS1 URA3 IRO1</i>	59
<i>git2,3,4Δ/Δ</i> + pDDB78	<i>arg4Δ leu2Δ his1Δ ura3Δ::imm434 iro1Δ::imm434</i>	59
<i>git2,3,4Δ/Δ</i> + pDDB78GIT2	<i>arg4Δ leu2Δ his1Δ URA3 IRO1 pho4::LEU2</i>	59
<i>git2,3,4Δ/Δ</i> + pDDB78GIT3	<i>arg4Δ leu2Δ his1Δ ura3Δ::imm434 iro1Δ::imm434 pho4::HIS1</i>	This study
<i>git2,3,4Δ/Δ</i> + pDDB78GIT4	<i>ura3Δ::λimm434 arg4::hisG his1::hisG::pHIS1 git2,3,4::ARG4</i>	This study
<i>gde1Δ/Δ</i> + pDDB78	<i>ura3Δ::λimm434 arg4::hisG his1::hisG git2,3,4::URA3</i>	This study
<i>gde1Δ/Δ</i> + pDDB78GDE1	<i>ura3Δ::λimm434 arg4::hisG his1::hisG::pHIS1-GIT2 git2,3,4::ARG4</i>	This study
<i>git3Δ/Δ</i>	<i>ura3Δ::λimm434 arg4::hisG his1::hisG git2,3,4::URA3</i>	This study
<i>git4Δ/Δ</i>	<i>ura3Δ::λimm434 arg4::hisG his1::hisG::pHIS1-GIT3 git2,3,4::ARG4</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG git2,3,4::URA3</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG::pHIS1-GDE1 gde1::ARG4</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG gde1::URA3</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG::pHIS1-GIT4 git2,3,4::ARG4</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG git2,3,4::URA3</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG::pHIS1-GIT3 git2,3,4::ARG4</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG git2,3,4::URA3</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG::pHIS1-GDE1 gde1::ARG4</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG gde1::URA3</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG git3::dpl200</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG git3::dpl200</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG git4::dpl200</i>	This study
	<i>ura3Δ::λimm434 arg4::hisG his1::hisG git4::dpl200</i>	This study

17, 19, 20), known locations for *C. albicans* colonization (1, 21). In the renal medulla of the kidney, where there is risk of *C. albicans* infection in critically ill patients (1), GroPCho serves as a protective osmolyte against a high concentration of NaCl and urea (12, 13). Additionally, GroPCho is found in the brain and spinal fluid (16, 18).

We have reported that *C. albicans* transports glycerophosphodiesteres, specifically GroPIIns and GroPCho, into the cell where they are hydrolyzed and used as a source of phosphate, choline, and inositol (22). *GIT1*, identified based on sequence similarity to *S. cerevisiae* *GIT1*, was shown to be responsible for GroPIIns transport but not GroPCho transport. GroPCho transport is roughly 50 times greater in *C. albicans* as compared with *S. cerevisiae*, and three other ORFs (*GIT2,3,4*; 19.1978–19.1980) with similarity to *GIT1* exist in the *C. albicans* genome (22). *GIT2,3,4* lie in a tandem repeat on chromosome 5 and, like *GIT1*, are members of the major facilitator superfamily (23).

In this study, we have identified several gene products involved in the utilization of the common phospholipid metabolite, GroPCho (Fig. 10A). We have identified *Git3* and *Git4* as GroPCho transporters, with *Git3* exhibiting the major activity. In addition, we have identified *Gde1* as a glycerophosphodiesterase involved in intracellular GroPCho catabolism and have shown that *Pho4* is a regulator of *GIT3*, *GIT4*, and *GDE1* expression. Based on extensive labeling studies, we determined that *C. albicans* employs multiple mechanisms for GroPCho utilization. Our finding that *GIT3* is required for full virulence in a mouse model underlines the importance of metabolic studies in garnering a full understanding of *C. albicans* biology and pathogenicity.

## EXPERIMENTAL PROCEDURES

**Strains and Media**—*C. albicans* strains used in this study can be found in Table 1. Strains were grown aerobically at 30 °C unless otherwise noted. Turbidity was monitored by measurement of absorbance at 600 nm ( $A_{600}$ ) on a BioMate 3 Thermo Spectronic spectrophotometer. Medium used for this study was synthetic complete (yeast nitrogen base (YNB)) containing 2%

glucose, as described previously (24). Media phosphate concentrations were controlled by removing  $\text{KH}_2\text{PO}_4$  (1 g/liter) from the synthetic mix and replacing it with KCl (1 g/liter).  $\text{KH}_2\text{PO}_4$  was added back into media at high (10 mM) or low (200  $\mu\text{M}$ ) concentrations as indicated. In some experiments, media contained GroPCho (200  $\mu\text{M}$ ) (Sigma catalog no. G5291). For all experiments, the medium was supplemented with 80  $\mu\text{g}/\text{ml}$  uridine. For serum experiments, bovine serum (Sigma catalog no. B9433) was added to synthetic complete YNB media containing  $\text{KH}_2\text{PO}_4$  (1 mM) at 10% of the total volume. Strains were maintained on YEPD agar plates (yeast extract 10 g, peptone 20 g, and dextrose 10 g per liter).

**Construction of Homozygous Mutants**—Primers used in this study are listed in Table 2. The wild type strain (DAY185) and methodology for creating homozygous deletion mutants have been described previously (25, 26). In general, a forward deletion primer consisted of 100 nt homologous to the upstream region of the gene's start site plus an adaptor sequence (5'-TTTCCCAGTCACGACGTT-3') that flanked the 5' end of the *URA3* gene in plasmid pGEM-*URA3* (JVE278) (26). A reverse deletion primer consisted of 100 nt of homology downstream of a gene's stop site plus an adaptor sequence (5'-GTGGAATT-GTGAGCGGATA-3') that flanked the 3' end of the *URA3* gene in plasmid pGEM-*URA3*. The 1.4-kb PCR product containing the *URA3* gene was transformed into strain BWP17, and  $\text{Ura}^+$  transformants were selected. Identical primers were used to PCR-amplify the *ARG4* gene from plasmid pRS-*ARG4* (JVE279) (26) for deletion of the second allele because the same adaptor sequence was contained in both plasmids pGEM-*URA3* and pRS-*ARG4*. The ~2.5-kb PCR product containing the *ARG4* gene was transformed into the heterozygous mutant strain, and  $\text{Ura}^+ \text{Arg}^+$  transformants were selected. A homozygous deletion mutant would produce PCR products for both the inserted *URA3* gene (1.2 kb) and inserted *ARG4* gene (2.3 kb) but not the native locus. Using this methodology, a strain, *git2,3,4Δ/Δ* (JPV 692/SGH338) was produced using a forward primer with homology upstream of the *GIT2* start site and a

**TABLE 2**  
Deletion primers used in this study

Gene name	Primer	Sequence 5'–3'
<i>GIT2</i>	Forward	ATTACAACAATCCCAAATTTAGTACTTTAACATCAAAATGCAATCTTTCACATACATGTAACACGCTTTTTTAATTACGTA TCGTGAACAATCCCAAATTTATGGTTATGTAAATACTAGGTTTCCAGTCACGACGTT
<i>GIT3</i>	Forward (A)	CATTTCCATCATCTATCTTATCTTATCTTATCTTTTTTTTATTTGGTCATACACTTATACATATATCTTTTTTTGTTTGAAC TTCTACTGACTTTTACAAATTTTCCAGTCACGACGTT
<i>GIT3</i>	Reverse (A)	TACGTTAAAATGCTCTAACTATATATATAAAATGTGCTCCCAAAAGCGTCCAGTCAAATGAGATATAATAAATACTGTTT TATGCAAAACTATAAACTAGTGGAAATTTGTGAGCGGATA
<i>GIT3</i>	Forward (B)	CTACTAGAGATTTACCTCATAGTTTTTCCGAGTTGAGTTATGGCTGGGTGAAAGAATACGTGCTGAATTCACCGTTGGG AAAAGTAAAGAACAATTTCTCCAGTCACGACGTT
<i>GIT3</i>	Reverse (B)	AAGAGAATTATTTGCAACTTGGAAATCATCTCTTTTTTCCCTTTTCAAGTGAAGTCTGATTCACGACAAAATTCACGAACATC ACCACCTTCTCCCAACATAGTGGAAATTTGTGAGCGGATA
<i>GIT4</i>	Forward (A)	TAAATTTGGGATTCAAATTTCCCTTACATATTTTTTATTTCCCTTTTTGTCCAAGAAGACTCTAAACCATTCAATCCTAATTTA AATAATCATATCATATCATTTTTTCCAGTCACGACGTT
<i>GIT4</i>	Reverse (A)	TCACTCAAACGTTAAACAATAATAAATCTAATATATTTATATAAAAGCAAATACAAAACCTTACACCTGCAAAGTTG AACCTCCGCTTAGTATCTGGTGGAAATTTGTGAGCGGATA
<i>GIT4</i>	Forward (B)	GCTACTAGAGATTTACCTCATTCAGTTGGTGACTTTTTTGGTTGGGTTGATCAAATTCGAAGTGAATCAGTTTAGGTA AAAGTCAAGATCAATTAATTTCCAGTCACGACGTT
<i>GIT4</i>	Reverse (B)	TACATTTTTCTGTTGACTTTAACGGTATCGTCTTTTTCATCAGAAATCACACCAATATCTTCATCTTCTTGATATGAGT GACAACACCACATACCTGTGGAAATTTGTGAGCGGATA
<i>GDE1</i>	Forward	TATTCATTTGTTGTTGTTGTTGTTTCTTTCTTTCTTTTTTCCCTGTGT GTGTGTGTTTGTGGAAATAGTTTAAACGGTTATTTAGTTTCAATTCCCATTCCCAGTCACGACGTT
<i>GDE1</i>	Reverse	TAGTAAGTACATCGTGATACAACAATGCATGTAAAGAATCCAAGAAACAACAACTAACAAATCTATATCTCTCTC TAATTTAGTATTTAATATATAAAATTTGTGGAAATTTGTGAGCGGATA

reverse primer with homology downstream of the *GIT4* stop site. The resulting homozygous mutant lacked ~8500 kb encompassing *GIT2* through *GIT4*.

For two strains (*git3Δ/Δ* and *git4Δ/Δ*), homozygous deletions were made utilizing the *URA3* cassette described above, but following heterozygous mutant verification, 5-fluoroorotic acid counterselection was performed (25). For deletion of the second allele, a secondary set of deletion primers (B set in Table 2) was necessary for both *GIT3* and *GIT4* because of the tendency of the *URA* cassette to combine at the deletion site of the first allele. This second group of primers was similar to the first set (labeled A in Table 2) but consisted of a forward primer with 100 nt homologous to the region downstream of the gene's start site plus an adaptor sequence and a reverse primer that consisted of 100 nt homologous to the region upstream of the gene's stop site. This second *URA3* cassette was transformed into the heterozygous mutant strain; deletion of the second native allele was verified, and counterselection on 5-fluoroorotic acid was repeated producing a *Ura*<sup>−</sup> homozygous deletion mutant.

**Construction of Complementation Plasmids**—Complementation plasmids were constructed for *GIT2*, *GIT3*, *GIT4*, and *GDE1* using plasmid pDDB78 (25). Each target gene was amplified from genomic DNA using primers that can be found in Table 3. Each forward primer was located ~1500 bp upstream from the start site and contained a 5' NotI restriction site plus 100 nt of homology to the genomic DNA. The reverse primer was located ~300 bp downstream of the stop site and contained a 5' EcoRI restriction site plus 100 nt of homology to the genomic DNA. Upstream and downstream locations varied depending on intergenic distances and neighboring ORFs. The vector pDDB78 was linearized with restriction enzymes NotI and EcoRI. The linear pDDB78 and amplified target gene were transformed into *S. cerevisiae* strain (*trp1Δ63*, *his3Δ200*, *ura3-52*, and *leu2Δ1*) (JPV1) (25) for *in vivo* recombination, and *Trp*<sup>+</sup> colonies were selected. Plasmids were extracted from *Trp*<sup>+</sup> colonies using acid-washed beads and a Zippy Mini prep kit (Zymo). Extracted plasmids were then transformed into

**TABLE 3**  
Complementation primers used in this study

Gene name	Primer	Sequence 5'–3'
<i>GIT2</i>	Forward	TTCACACAGGAAACAGCTATGACCATGATT ACGCCAAGCTAAATTTGATTCTGCCGTGCC
<i>GIT2</i>	Reverse	TCGACCATATGGGAGAGCTCCCAACGCGTT GGATGCATAGATTTACCCGGAATCAACCCC
<i>GIT3</i>	Forward	TTCACACAGGAAACAGCTATGACCATGATT ACGCCAAGCTGGGTTGATTCCGGGTAATG
<i>GIT3</i>	Reverse	TCGACCATATGGGAGAGCTCCCAACGCGTT GGATGCATAGTCCAGTTGTCAGAGAGTTCA
<i>GIT4</i>	Forward	TTCACACAGGAAACAGCTATGACCATGATT ACGCCAAGCTTATCTCATTTGACTGGACGC
<i>GIT4</i>	Reverse	TCGACCATATGGGAGAGCTCCCAACGCGTT GGATGCATAGAATAGTGGCGACACTGTTG
<i>GDE1</i>	Forward	TTCACACAGGAAACAGCTATGACCATGATT ACGCCAAGCTACCAGTCTGTCTTTCTTTCA
<i>GDE1</i>	Reverse	TCGACCATATGGGAGAGCTCCCAACGCGTT GGATGCATAGGGATGACATTTGAGTCTGTAG

*E. coli*, and Amp<sup>+</sup> plasmids were selected. The plasmids were extracted from *E. coli* and verified by PCR and agarose gel electrophoresis.

**Insertional Complementation of Deletion Mutants**—Plasmids pDDB78*GIT2*, pDDB78*GIT3*, pDDB78*GIT4*, and pDDB78*GDE1* were linearized with NruI, which cuts the plasmids within the *HIS1* gene. Linearized pDDB78*GIT2*, pDDB78*GIT3*, and pDDB78*GIT4* plasmids were then transformed into *git2*, *3,4Δ/Δ* (JPV 692/SGH338), and linearized pDDB78*GDE1* was transformed into *gde1Δ/Δ* (JPV 733) for recombination at the *HIS1* locus. His<sup>+</sup> transformants were tested for complementation of the mutant phenotype when possible. Reintegration was also verified by PCR. Empty plasmid pDDB78 was also linearized and transformed into both *git2,3,4Δ/Δ* and *gde1Δ/Δ* strains.

**[<sup>3</sup>H]GroPCho Transport Assays**—Short term transport assays were performed as described previously (22). Briefly, cultures were grown to log phase at 30 °C. Aliquots were harvested, washed once in sterile DI H<sub>2</sub>O, and suspended in 100 mM citrate buffer (pH 5) to an A<sub>600</sub> of 5. Cell suspensions were incubated at 30 °C for 10 min with agitation to allow for equilibration to buffer conditions. The assay was started by the addition of 50 μl of 1 mM [<sup>3</sup>H]GroPCho to 200 μl of cell suspension



## GroPCho Transport and Utilization by *C. albicans*

making a final concentration of 200  $\mu\text{M}$  [ $^3\text{H}$ ]GroPCho. After 2 min of incubation at 30 °C, the assay was stopped by the addition of 10 ml of ice-cold DI H<sub>2</sub>O. The samples were immediately filtered through glass fiber (GF/C) filters (Whatman number 1822-025). The filters were washed once with ice-cold DI H<sub>2</sub>O and suspended in 10 ml of scintillation fluid. Radioactivity was measured by liquid scintillation counting. Tritium-labeled GroPCho ([ $^3\text{H}$ ]choline-GroPCho) was produced through the chemical deacylation of phosphatidylmethyl[ $^3\text{H}$ ]choline (American Radiolabeled Chemicals) as described previously (27).

To determine GroPCho transport kinetics, the initial rate of GroPCho uptake was determined as described above but with varying concentrations of GroPCho. For measuring Git3 kinetics in a *git4* $\Delta/\Delta$  mutant, a concentration range of 20  $\mu\text{M}$  to 1 mM was used. For measuring Git4 kinetics in a *git3* $\Delta/\Delta$  mutant, 5–200  $\mu\text{M}$  was used. Saturation kinetics data for GroPCho were analyzed to determine estimated  $K_m$  and  $V_{\text{max}}$  values using the Levenberg-Marquardt algorithm for nonlinear regression in GraphPad Prism (version 4.0). Values were determined by least squares fitting of the data to the Michaelis-Menten equation ( $V = V_{\text{max}}[S] \cdot (K_m + [S])^{-1}$ ), where  $S$  represents GroPCho. Linearization of the kinetic data was performed using Hanes plot transformations (28).

**Preparation of External and Internal Cellular Fractions and Analysis of [ $^3\text{H}$ ]Choline-containing Metabolites by Ion-exchange Chromatography**—[ $^3\text{H}$ ]Choline-containing metabolites were analyzed in both intracellular and extracellular fractions of the cell following short term transport assays and long term incorporation studies. For the short term studies, a standard 2-min transport assay was performed except that the assay was not stopped with 10 ml of DI H<sub>2</sub>O. Rather, 750  $\mu\text{l}$  of H<sub>2</sub>O was added to the 250- $\mu\text{l}$  cell suspension. The cells were pelleted, and the supernatant was removed as the extracellular fraction. The pellet was washed once in 500  $\mu\text{l}$  of DI H<sub>2</sub>O and pelleted. The supernatant was again removed to the extracellular fraction.

To isolate an internal fraction (29), the cell pellet was suspended in 100  $\mu\text{l}$  of 5% TCA solution followed by a 10-min incubation on ice. Cells were again pelleted, and the supernatant was removed as the internal fraction. To neutralize the TCA, an equal volume of 1 M Tris (pH 8) was added to the TCA fraction. The cell pellet was washed once with 300  $\mu\text{l}$  of DI H<sub>2</sub>O, and the supernatant was added to the internal fraction.

Long term incorporation studies were designed to analyze label uptake incrementally over 24 h. The assay was started by inoculating 2.2-ml cultures of synthetic complete YNB media containing 200  $\mu\text{M}$  KH<sub>2</sub>PO<sub>4</sub> and 50  $\mu\text{M}$  [ $^3\text{H}$ ]GroPCho to an  $A_{600}$  of 0.05. At 6, 12, 18, and 24 h after inoculation, 400  $\mu\text{l}$  of culture was removed. Cells were pelleted, and the extracellular fraction was removed. When necessary, nonradioactive cells were added to aid in the pelleting of radioactive cells. Pellets were washed with 600  $\mu\text{l}$  of DI H<sub>2</sub>O and again sedimented. The pellet was suspended 100  $\mu\text{l}$  of 5% TCA solution followed by a 10-min incubation on ice. Cells were again pelleted, and the TCA fraction was removed as the internal fraction. To neutralize the TCA, an equal volume of 1 M Tris (pH 8) was added to the TCA fractions. The cells were washed once with 300  $\mu\text{l}$  of DI H<sub>2</sub>O and pelleted, and the supernatant was removed to the internal fraction. Internal and external samples were diluted 4 $\times$  in DI

**TABLE 4**  
Real time qPCR primers used in this study

Gene name	Primer	Sequence 5'-3'
<i>GIT2</i>	Forward	GGTGCCTTTTCTGCTGATTA
<i>GIT2</i>	Reverse	CCAAATTCACCAATGTAGC
<i>GIT3</i>	Forward	TTGCTAGAAAAGGAGGGATG
<i>GIT3</i>	Reverse	AAAGCTGAAACAACGAAACC
<i>GIT4</i>	Forward	GTATTGCCATGTCAGCATGT
<i>GIT4</i>	Reverse	TGAAAAGACACAAGGCAGAA
<i>GDE1</i>	Forward	CTGGTTTCAGATGATGGAAC
<i>GDE1</i>	Reverse	TCCGTAGCAAAAACCTTAGC
<i>TDH3</i>	Forward	TGCTAAAGCCGTTGGTAAGG
<i>TDH3</i>	Reverse	AAATCGGTGGAGACAACAGC

H<sub>2</sub>O, applied to 250- $\mu\text{l}$  Dowex 50W8, 200–400 anion-exchange columns, and eluted as described previously (30). Briefly, [ $^3\text{H}$ ]GroPCho was eluted with 2 $\times$  1-ml H<sub>2</sub>O washes. [ $^3\text{H}$ ]Choline-phosphate, if present, was eluted with a subsequent 1-ml H<sub>2</sub>O wash. [ $^3\text{H}$ ]Choline was eluted with 5 ml of 1 M HCl. Standards were used to verify that columns were functioning correctly. Radioactivity in each sample was determined using liquid scintillation counting.

**RNA Extraction and Gene Expression Analysis by Real Time Quantitative PCR**—RNA extraction and quantitative RT qPCR procedures were performed as described previously (22). Briefly, strains were grown in low (200  $\mu\text{M}$ ) or high (10 mM) phosphate media described above. Cultures were grown to  $A_{600}$  between 0.8 and 1.2 and harvested, and RNA was extracted using a hot phenol/chloroform extraction (31). RNA was DNase-treated using the Turbo DNA-free kit (Applied Biosystems) and stored at  $-80^\circ\text{C}$  until analysis. Primer 3 software was used to design forward and reverse RT qPCR primers for *TDH3*, *GIT2*, *GIT3*, *GIT4*, and *GDE1* (Table 4). RT qPCR was carried out on an Applied Biosystems StepOnePlus instrument using Power SYBR Green RNA to a  $C_T$  one-step kit (Applied Biosystems). Each reaction consisted of 0.2  $\mu\text{l}$  of a 125 $\times$  RT enzyme mixture, 12.5  $\mu\text{l}$  of a 2 $\times$  RT-PCR mixture, 1  $\mu\text{M}$  primers, and 1.5  $\mu\text{l}$  of DNase-treated RNA brought up to a volume of 25  $\mu\text{l}$  with diethyl pyrocarbonate-treated H<sub>2</sub>O. Experimental samples were performed in triplicate and are representative of three independent determinations. Reverse transcription was performed at 50 °C for 15 min, followed by 95 °C for 15 min for RT inactivation and polymerase activation. This was followed by 40 cycles at 95 °C for 15 s, 50 °C for 30 s for primer annealing, and 72 °C for 40 s for amplification. Primers were validated for specificity through melt curve analysis and by visualizing amplicons by gel electrophoresis. Primer sets did not produce an amplicon when the template from the respective deletion mutant was employed. Control reactions lacking reverse transcriptase or template were performed. Expression levels were analyzed using the  $\Delta\Delta C_T$  method (32) and normalized to the endogenous control, *TDH3*, which is not phosphate-regulated. For experiments determining the change in expression due to phosphate concentrations, wild type (DAY185) low phosphate expression was normalized to 1 and used to compare fold change in high phosphate expression. For experiments determining the change in expression due to *PHO4*, wild type (WT-TF) low phosphate expression was normalized to 1 and used to compare fold change in the *pho4* $\Delta/\Delta$  strain under low phosphate conditions.

**[<sup>3</sup>H]GroPCho Uptake in Serum and XTT Cell Proliferation Assay**—Parallel radioactive and nonradioactive experiments were performed. Nonradioactive cultures were used to assess cell growth using the XTT cell proliferation assay kit (Abnova). This assay measures the reduction of XTT through the production of a colorimetric product and was previously used to monitor cell proliferation in *C. albicans* biofilms (33). Cultures (1 ml) of synthetic complete media (1 mM KH<sub>2</sub>PO<sub>4</sub>) containing 10% bovine serum were inoculated to an A<sub>600</sub> of 0.1. For the radioactive samples, the media were supplemented with 200 μM [<sup>3</sup>H]GroPCho, whereas 200 μM GroPCho was used in the nonradioactive samples. Cultures were grown at 37 °C with agitation for 6 h. Following the incubation period, the radioactive samples were centrifuged at 3500 rpm for 4 min to pellet the cellular mass. The 1-ml supernatant was carefully removed as the extracellular fraction. Pellets were washed with 500 μl of DI H<sub>2</sub>O and centrifuged again removing the supernatant to the extracellular fraction. The pellet was suspended 100 μl of 5% TCA solution followed by 10 min of incubation on ice. Cells were again pelleted, and the TCA fraction was removed as the internal fraction. To neutralize the TCA, an equal volume of 1 M Tris (pH 8) was added to the TCA fractions. The cells were washed once with 300 μl of DI H<sub>2</sub>O and pelleted, and the supernatant was removed to the internal fraction. Internal [<sup>3</sup>H]choline-containing metabolites were separated by ion-exchange chromatography as described under “Experimental Procedures.”

Cell growth was assessed in nonradioactive cultures using the XTT kit because the presence of serum induced hyphae formation and clumping cells whose growth could not be monitored by measuring optical density. After 6 h of growth, 10 μl of XTT reagent mixture was added to each 1-ml culture and carefully mixed with a pipette. Tubes were incubated upright at 37 °C for 4 h. Tubes were centrifuged at 3500 rpm for 4 min to pellet cells, and 50 μl of supernatant was diluted 10-fold in DI H<sub>2</sub>O. Absorbance was measured at 450 nm, and this number was used to normalize radioactive uptake of [<sup>3</sup>H]GroPCho to approximate cellular growth across the different strains.

**Mouse Model of Blood Stream Infection**—The standard mouse model of hematogenously disseminated candidiasis was used. Eight male BALB/c mice per strain were injected via the tail vein with 5 × 10<sup>5</sup> *C. albicans* cells. Survival was monitored three times daily for 21 days. Differences in survival among mice infected with the different strains were analyzed by the log-rank test.

**Phylogenetic Analyses**—Homologs of *C. albicans* Git1, Git2, Git3, and Git4 proteins were identified with a BLASTP search of known and predicted proteins in the NCBI nr database from the following species of the “CTG clade”: *Candida dubliniensis*, *Candida tropicalis*, *Candida maltosa*, *Candida orthopsilosis*, and *Candida parapsilosis*, along with other members of the Saccharomycetales: *Kluyveromyces lactis*, *S. cerevisiae*, and the more distantly related *Yarrowia lipolytica*. Hits with greater than 30% identity and greater than 50% coverage in the matches to *C. albicans* proteins were aligned with Clustal Omega software (34). Maximum likelihood and neighbor-joining phylogenetic trees were constructed using MEGA Version 5.2.2 software (35), with the JTT matrix-based method excluding all positions containing gaps or missing data (complete deletion

**TABLE 5****Sequence comparisons among *C. albicans* Git proteins**

Percent identity between homologs shown below diagonal; percent positive matches shown above diagonal.

	Git1	Git2	Git3	Git4
Git1		51.7	50.4	53.2
Git2	33.0		86.6	81.4
Git3	34.1	75.3		83.3
Git4	35.3	69.4	73.7	

option) with statistical confidence of nodes assessed with 10,000 bootstrap replicates.

**RESULTS**

**Novel Construction of a Strain Lacking GIT2,3,4**—*C. albicans* contains four ORFs (*GIT1,2,3,4*) that are predicted to be involved in glycerophosphodiester transport. *GIT1*, residing on chromosome 2, codes for a permease that is solely responsible for the uptake of GroPIns but does not have specificity for GroPCho, a highly transported metabolite in *C. albicans* (22). The remaining three ORFs, *GIT2,3,4*, lie in a tandem repeat on chromosome 5 and are the focus of this work. Pairwise alignment of Git3 with Git2 using NCBI BLAST (36) reveals that the Git2, Git3, and Git4 proteins are all similar to each other, ranging from 69 to 75% identity and with 81–87% positive matches (Table 5). In contrast, these three proteins are equally much more divergent from Git1, ranging from 33 to 35% identical and 50–53% positive matches to Git1. Because the *GIT2,3,4* gene products are very similar to each other, we reasoned that single mutation phenotypes might be difficult to detect because of compensation by the other ORFs. Thus, in addition to constructing single gene deletion mutants, we also constructed a triple mutant by deleting the region from *GIT2* to *GIT4* spanning roughly 8500 bp. To the best of our knowledge, this is the first report of a triple mutant being created by knocking out three genes in tandem in *C. albicans*.

**Role of GIT3 and GIT4 in the Utilization of GroPCho as a Phosphate Source**—*S. cerevisiae* and *C. albicans* can utilize glycerophosphodiesters as phosphate sources (22, 37). To assess the role of Git2,3,4 in this process, we examined the growth of a *git2,3,4Δ/Δ* mutant when GroPCho was provided as the sole phosphate source (Fig. 1A). Early growth (just detectable roughly 18 h post-inoculation) was abolished in the *git2,3,4Δ/Δ* mutant, although growth did resume after that. Reintegration of either *GIT3* or *GIT4* into the genome of the *git2,3,4Δ/Δ* mutant rescued this early growth defect on GroPCho, although reintegration of *GIT2* or the empty vector (pDDB78) did not. All strains grew uniformly when KH<sub>2</sub>PO<sub>4</sub> was supplied (Fig. 1B), and only background growth was observed in the absence of a phosphate source (Fig. 1C).

**Git3 Is the Major GroPCho Permease and Is Regulated by Phosphate Availability**—Because both *GIT3* and *GIT4* rescued the growth defect observed in a *git2,3,4Δ/Δ* strain, we next monitored the initial rate of [<sup>3</sup>H]GroPCho uptake. Cells were pre-grown in synthetic media containing either 200 μM (low) or 10 mM (high) KH<sub>2</sub>PO<sub>4</sub>, since we showed previously that [<sup>3</sup>H]GroPCho uptake is regulated by phosphate availability (22). Reintegration of *GIT3* rescued a majority of the transport activity lost by the deletion of *GIT2,3,4* (Fig. 2A). Reintegration

## GroPCho Transport and Utilization by *C. albicans*




FIGURE 1. Both *GIT3* and *GIT4* rescue growth of a *git2,3,4*Δ/Δ mutant utilizing GroPCho as the sole phosphate source. Strains were grown in synthetic YNB liquid media lacking a phosphate source (C) and supplemented with 200 μM KH<sub>2</sub>PO<sub>4</sub> (B) or with 200 μM GroPCho (A). Cultures were incubated at 30 °C with shaking, and A<sub>600</sub> readings were taken incrementally over 48 h. Values represent means ± S.E. of triplicate determinations. Strains are WT-DAY185 or *git2,3,4*Δ/Δ complemented with empty vector (pDDB78), *GIT2* (pDDB78GIT2), *GIT3* (pDDB78GIT3), or *GIT4* (pDDB78GIT4).



FIGURE 2. *Git3* exhibits greater initial transport velocity than *Git4* and is regulated by phosphate availability. A, strains grown to log phase in synthetic YNB media containing either 200 μM KH<sub>2</sub>PO<sub>4</sub> (L) or 10 mM KH<sub>2</sub>PO<sub>4</sub> (H) were harvested and assayed for their ability to transport [<sup>3</sup>H]GroPCho in 2-min assays. B, enlargement of *git2,3,4*Δ/Δ + pDDB78GIT4 (L) from A compared with uptake of [<sup>3</sup>H]GroPIns by WT-DAY185 strain grown under low phosphate conditions. Values represent means ± S.E. of triplicate determinations. Strains are WT-DAY185 or *git2,3,4*Δ/Δ complemented with empty vector (pDDB78), *GIT2* (pDDB78GIT2), *GIT3* (pDDB78GIT3), or *GIT4* (pDDB78GIT4).

of *GIT4* also rescued initial [<sup>3</sup>H]GroPCho transport, albeit at a much lower level than *GIT3*. On an adjusted scale (Fig. 2B), it is evident that [<sup>3</sup>H]GroPCho uptake through *Git4* is not trivial but is comparable with the [<sup>3</sup>H]GroPIns uptake that is observed in a wild type strain and mediated by *Git1* (22). This level of GroPIns transport is enough to support growth that is indistinguishable from that which occurs when free KH<sub>2</sub>PO<sub>4</sub> is supplied as the phosphate source (22). Thus, it is not surprising that the GroPCho transport activity provided by *GIT3* when reintegrated into a *git2,3,4*Δ/Δ strain is not growth-limiting when compared with wild type using either GroPCho (Fig. 1A) or KH<sub>2</sub>PO<sub>4</sub> (Fig. 1B) as the phosphate source.

Growth in high phosphate reduced both [<sup>3</sup>H]GroPCho uptake and the mRNA levels of *GIT3* and *GIT4* as determined by RT qPCR (Table 6). Although we have not identified a role for *GIT2*, we examined its expression and found it to be largely unresponsive to phosphate levels (Table 6).

We have previously reported that *Git1* is the sole transporter for GroPIns based on the absence of transport in the *git1*Δ/Δ mutant (22). For completeness, we measured GroPIns transport in a wild type and *git2,3,4*Δ/Δ mutant and found no decrease in transport activity upon loss of *GIT2,3,4* (100 ± 8% for wild type versus 115 ± 3% for the triple mutant). Thus, neither *Git2*, *Git3*, nor *Git4* possess detectable GroPIns transport activity.



**Loss of *GDE1* Alters GroPCho Catabolism**—Because an initial goal of this work was to abrogate GroPCho utilization and deletion of *GIT2*, *GIT3*, and *GIT4* did not achieve that, we deleted a gene predicted to be involved in GroPCho catabolism. A single ORF in the *C. albicans* genome has sequence similarity to *S. cerevisiae GDE1* (YPL110C), which codes for a protein with glycerophosphodiesterase activity specific for GroPCho (38, 39). Using NCBI BLAST (36) (default settings, CGD) ORF 19.3936, here named Gde1, was found to have 42% identity match and 58% positive match to Gde1 with 15% gaps. *GDE1* is predicted to encode a cytosolic protein of 1162 amino acids. Homozygous deletion of *GDE1* did not abolish the cells' ability to utilize GroPCho as a sole phosphate source, although there was a measurable difference between wild type and the *gde1Δ/Δ* strain (Fig. 3A). The difference in growth was rescued when a copy of *GDE1* (pDDB78GDE1) was reintegrated into the genome of *gde1Δ/Δ* (Fig. 3A). To assess the role of Gde1 in GroPCho catabolism, we performed transport assays followed by analysis of the internal metabolites. As shown in Fig. 3B, internal [<sup>3</sup>H]GroPCho as well as [<sup>3</sup>H]choline were present in a wild type strain. In the homozygous deletion mutant, we observed a buildup of internal [<sup>3</sup>H]GroPCho and minimal levels of [<sup>3</sup>H]choline. Reintegration of one copy of *GDE1* resulted in wild type levels of [<sup>3</sup>H]GroPCho and [<sup>3</sup>H]choline, suggesting that *GDE1* codes for a glycerophosphodiesterase that acts on GroPCho. A *git2,3,4Δ/Δ* was also included to show that GroPCho is not internalized in the absence of a transporter. Growth in the presence of high phosphate reduced the expression of *GDE1*, as was the case for *GIT3* and *GIT4* (Table 6).

***C. albicans* Can Utilize GroPCho through Transport and Intracellular Hydrolysis or through Extracellular Hydrolysis**—Our transport assays indicate that either Git3 or Git4 is

required for GroPCho uptake (Fig. 2), yet growth on GroPCho as a phosphate source does occur roughly 12 h post-inoculation in a *git2,3,4Δ/Δ* mutant (Fig. 1A). To gain insight into these results, we analyzed the extracellular and intracellular water-soluble fractions of cells inoculated in the presence of [<sup>3</sup>H]GroPCho over the course of 24 h. For these experiments, the medium was supplemented with 200 μM KH<sub>2</sub>PO<sub>4</sub> in addition to [<sup>3</sup>H]GroPCho to supply a phosphate source for initial growth of the *git2,3,4Δ/Δ* mutant. Focusing on the internal fraction of the wild type strain (Fig. 4A), the level of [<sup>3</sup>H]GroPCho seen at 6 h decreased thereafter, and a parallel increase of internal free [<sup>3</sup>H]choline occurred. These data suggest that the internal GroPCho is being hydrolyzed initially to [<sup>3</sup>H]choline and glycerol 3-phosphate (GroP). By 24 h, the internal [<sup>3</sup>H]choline had been incorporated into PC (data not shown) and thus was not present in the water-soluble fractions. Outside of the cell, the level of [<sup>3</sup>H]GroPCho decreased with time as it was transported into the cell and reached a plateau at ~12 h (Fig. 4B). Notably, [<sup>3</sup>H]choline appeared in the extracellular fraction starting at ~6 h, suggesting that external hydrolysis was occurring parallel to GroPCho transport (Fig. 4B).


In the *git2,3,4Δ/Δ* mutant, we were unable to detect any significant levels of internal [<sup>3</sup>H]GroPCho over 24 h of growth (Fig. 4C), indicating that deletion of *GIT2,3,4* abolishes GroPCho transport activity, even over 24 h. After 12 h of growth, however, we were able to detect internal [<sup>3</sup>H]choline in the *git2,3,4Δ/Δ* mutant (Fig. 4C), as well as a decrease in extracellular [<sup>3</sup>H]GroPCho (Fig. 4D) and the appearance of external [<sup>3</sup>H]choline. These data suggest that [<sup>3</sup>H]GroPCho was being hydrolyzed outside of the cell to release free choline, as was the case for wild type (Fig. 4B). Because Git3 is the primary permease for GroPCho, we analyzed the *git2,3,4Δ/Δ* mutant with *GIT3* reintegrated into the genome to confirm that intracellular and extracellular levels of metabolites were returned to that of wild type (Fig. 4, E and F) in the presence of a GroPCho permease. For all experiments, radioactivity not accounted for in the extracellular and intracellular water-soluble fractions was detected in the membrane fraction by way of free choline incorporation into newly synthesized PC (data not shown).

In total, the data presented in Fig. 4 suggest that during the first 12 h of growth, wild type cells transport GroPCho into the cell (primarily via Git3) and hydrolyze it to release free choline

**TABLE 6**  
Gene expression as a function of phosphate availability

Wild type cells were grown to log phase in YNB liquid media containing either low (200 μM) or high (10 mM) P<sub>i</sub>. Expression was measured by RT-qPCR. *TDH3* was used as an endogenous control. For each gene, expression under low phosphate conditions was normalized to 1. Values represent means ± S.E. of triplicate determinations. Two independent experiments were performed for *GIT3*, *GIT4*, and *GDE1*.

Strain	Normalized fold expression			
	<i>GIT2</i>	<i>GIT3</i>	<i>GIT4</i>	<i>GDE1</i>
WT DAY185 (low P <sub>i</sub> )	1	1	1	1
WT DAY185 (high P <sub>i</sub> )	1.26 ± 0.09	0.32 ± 0.05	0.05 ± 0.01	0.25 ± 0.02



**FIGURE 3. Deletion of *GDE1* results in altered GroPCho catabolism.** A, strains were grown in synthetic YNB liquid media lacking phosphate and supplemented with 200 μM GroPCho. Cultures were incubated at 30 °C with shaking, and A<sub>600</sub> readings were taken over 48 h. B, strains were grown to log phase in synthetic YNB low phosphate media, harvested, and incubated with [<sup>3</sup>H]GroPCho for 2 min. Internal pools of [<sup>3</sup>H]GroPCho and [<sup>3</sup>H]choline were determined by ion-exchange chromatography. Values represent means ± S.E. of triplicate determinations. Strains are WT-DAY185 or *gde1Δ/Δ* complemented with empty vector (pDDB78) or *GDE1* (pDDB78GDE1).

## GroPCho Transport and Utilization by *C. albicans*




FIGURE 4. *C. albicans* can utilize GroPCho through transport and intracellular hydrolysis or through extracellular hydrolysis. Strains were grown in liquid YNB synthetic media containing 200  $\mu$ M  $\text{KH}_2\text{PO}_4$  in the presence of [<sup>3</sup>H]GroPCho. At each time point, samples were harvested and separated into extracellular and intracellular fractions. Each fraction was analyzed by ion-exchange chromatography to determine the distribution of counts into either [<sup>3</sup>H]GroPCho or [<sup>3</sup>H]choline. Values represent means  $\pm$  S.E. of duplicate determinations. *A*, intracellular, and *B*, extracellular fraction of WT-DAY185. *C*, intracellular, and *D*, extracellular fraction of *git2,3,4Δ/Δ* with an empty vector (pDDB78) reintegrated. *E*, intracellular, and *F*, extracellular fraction of *git2,3,4Δ/Δ* with *GIT3* (pDDB78GIT3) reintegrated.

and GroP. After 12 h, when there is little continued uptake of intact GroPCho, the most likely scenario is that GroPCho is hydrolyzed extracellularly and the resulting metabolites transported into the cell as needed.

*Pho4 Regulates the Expression of GIT3, GIT4, and GDE1*—As shown in Table 6, *GIT3*, *GIT4*, and *GDE1* message levels are up-regulated in response to low phosphate. The transcription factor Pho4 regulates the expression of *GIT1* and thereby the transport of GroPIns by *C. albicans* (22), and its homolog in *S. cerevisiae* is a known regulator of phosphate-responsive genes (40, 41). Thus, we examined the role of Pho4 in GroPCho metabolism. As shown in Fig. 5B, [<sup>3</sup>H]GroPCho transport activity was greatly reduced in the *pho4Δ/Δ* mutant grown under low phosphate conditions. RT qPCR analysis of gene expression (Fig. 5C) revealed an approximate 10-fold reduction in mRNA levels for both *GIT3* and *GDE1* in the *pho4Δ/Δ* strain

as compared with wild type. *GIT4* displayed a roughly 4-fold decrease in message levels in a *pho4Δ/Δ* strain as compared with wild type. Growth of a *pho4Δ/Δ* mutant was slightly diminished as compared with wild type when cells were grown on either low concentrations of  $\text{KH}_2\text{PO}_4$  or GroPCho (Fig. 5A). It is not surprising that the GroPCho transport activity remaining in the *pho4Δ/Δ* mutant (250 pmol/min/ODU) was enough to support growth on GroPCho, as that level of activity was also enough to support growth of the *git2,3,4Δ/Δ* strain with a copy of *GIT4* reintegrated (Fig. 1A).

*Kinetics of GroPCho Transport by Git3 and Git4*—Given that our results indicated that both Git3 and Git4 act as GroPCho transporters, we used a *git4Δ/Δ* mutant to analyze Git3 transport kinetics and a *git3Δ/Δ* mutant to analyze Git4 transport kinetics. For analyzing kinetics, strains were grown in synthetic media containing low phosphate. Initial transport of [<sup>3</sup>H]GroP-






FIGURE 5. **Pho4 regulates the expression of *GIT3*, *GIT4*, and *GDE1*.** A, wild type (WT-TF) and *pho4*Δ/Δ strains were grown in YNB media lacking phosphate (No  $P_i$ ), supplemented with either 200  $\mu\text{M}$   $\text{KH}_2\text{PO}_4$  (Low  $P_i$ ) or 200  $\mu\text{M}$  GroPCho. Cultures were incubated at 30 °C with shaking. B, strains were grown to log phase in low  $P_i$  medium. Cells were harvested, washed, and analyzed for their ability to transport [ $^3\text{H}$ ]GroPCho over 2 min. C, strains were grown to log phase in low  $P_i$  medium. Cells were harvested; RNA was extracted, and expression of *GIT3*, *GIT4*, and *GDE1* was measured by quantitative real time PCR. *TDH3* was used as an endogenous control. Fold change expression was calculated compared with WT strain for the transcription factor deletion set (WT-TF) (normalized to 1). Values represent means  $\pm$  S.E. of triplicate determinations. Experiments were repeated with similar results.

Cho by both *Git3* and *Git4* conformed to Michaelis-Menten kinetics (Fig. 6, A and B). Under the given conditions, *Git3* exhibited a  $V_{\text{max}}$  of  $3940 \pm 150$  pmol/min/ODU and a  $K_m$  of  $45 \pm 6$   $\mu\text{M}$ . *Git4* exhibited a  $V_{\text{max}}$  of  $340 \pm 40$  pmol/min/ODU and a  $K_m$  of  $16 \pm 7$   $\mu\text{M}$ . Data were transformed into a Hanes plot (Fig. 6, A and B, right panels) to verify linearity and the presence of a single transporter for each analysis. The larger error bars (Fig. 6B) observed for the minor transporter, *Git4*, as compared with the major transporter, *Git3*, are due to this relatively low transport activity being affected by small changes in cell density at inoculation as well as at cell harvesting.

**GroPCho Utilization under Serum Growth Conditions**—To explore GroPCho transport under conditions more similar to those experienced in a human host, we performed GroPCho incorporation experiments in the presence of 10% serum and 1 mM  $\text{KH}_2\text{PO}_4$ , which is within the phosphate concentration range reported for serum (42). Cultures were grown for 6 h at 37 °C in the presence of [ $^3\text{H}$ ]GroPCho, and the internal metabolites were analyzed (Fig. 7). Both [ $^3\text{H}$ ]GroPCho and [ $^3\text{H}$ ]choline were detected internally in a wild type strain. When *GIT2,3,4* were deleted, no internal radiolabeled metabolites were detected. Upon reintegration of *GIT3*, wild type levels of metabolites were observed. A minimal amount of [ $^3\text{H}$ ]GroPCho was detected when *GIT4* was reintegrated. A strain containing a homozygous deletion of *GDE1* exhibited a buildup of [ $^3\text{H}$ ]GroPCho and less [ $^3\text{H}$ ]choline compared with wild type levels. Upon reintegration of *GDE1*, internal metabolites returned to levels similar to wild type. These results indicate that both *Git3* and *Gde1* are active in the presence of serum, which is known to contain GroPCho (14, 15, 43).

**Loss of GroPCho Transport Activity Reduces Virulence in a Mouse Model of Blood Stream Infection**—Because GroPCho utilization occurs in the presence of serum (Fig. 7), we exam-






FIGURE 6. **Kinetics of GroPCho transport by *Git3* and *Git4*.** Strains were grown to log phase in synthetic YNB low phosphate media, harvested, washed, and assayed for initial rate of transport of [ $^3\text{H}$ ]GroPCho at varying concentrations of GroPCho. A, *Git3* transport activity was assayed in a *git4*Δ/Δ mutant with GroPCho concentration ranging from 20  $\mu\text{M}$  to 1 mM. B, *Git4* transport activity was assayed in a *git3*Δ/Δ mutant with GroPCho concentration ranging from 5 to 200  $\mu\text{M}$ . Data were linearized using Hanes plot transformations (A and B, right panels).

ined the role of GroPCho transport in virulence following blood stream infection (Fig. 8). Mice infected with the wild type strain displayed a median survival of 5 days. In contrast, a *git2,3,4*Δ/Δ mutant exhibited a median survival of 9 days, and reintegration of a single copy of *GIT3* into the *git2,3,4*Δ/Δ mutant restored wild type virulence levels ( $p < 0.0007$  for *git2,3,4*Δ/Δ +

## GroPCho Transport and Utilization by *C. albicans*




**FIGURE 7. GroPCho is transported and metabolized in the presence of serum.** Strains were pre-grown in synthetic YNB media containing 1 mM  $\text{KH}_2\text{PO}_4$  (YNB 1 mM  $\text{P}_i$ ). The assay was initiated by inoculating cultures of synthetic YNB 1 mM  $\text{P}_i$  medium containing 10% bovine serum and 200  $\mu\text{M}$  [<sup>3</sup>H]GroPCho to an  $A_{600}$  of 0.1. Cultures were incubated at 37 °C for 6 h with agitation. [<sup>3</sup>H]Choline metabolites in extracellular, intracellular, and membrane fractions were determined by ion-exchange chromatography followed by liquid scintillation counting. Cell growth was determined using XTT reduction analysis (Abnova) performed on parallel nonradioactive cultures. Results represent mean  $\pm$  S.E. of duplicate samples. Experiment was repeated with similar results. Strains are WT-DAY185, *git2,3,4Δ/Δ* complemented with empty vector (pDDB78), *GIT3* (pDDB78GIT3) or *GIT4* (pDDB78GIT), and *gde1Δ/Δ* complemented with empty vector (pDDB78) or *GDE1* (pDDB78GDE1).



**FIGURE 8. Loss of GroPCho transport activity reduces virulence in a mouse model hematogenously disseminated infection.** Mice were injected intravenously with WT-DAY185, *git2,3,4Δ/Δ* + pDDB78, and *git2,3,4Δ/Δ* + pDDB78GIT3 ( $n = 8$  per strain). Survival was monitored for 21 days.  $p < 0.0007$  for *git2,3,4Δ/Δ* + pDDB78 compared with both the WT-DAY185 and *git2,3,4Δ/Δ* + pDDB78GIT3 strains.

pDDB78 compared with both the WT and *git2,3,4Δ/Δ* + pDDB78GIT3). Thus, *GIT3* is required for full virulence in this infection model.

*Multiple Homologs of the Git Family Are Found in Many Candida Species*—*C. albicans* and its close relative *C. dubliniensis* each possess four paralogs of the Git family, which we have named Git1, Git2, Git3, and Git4 (Fig. 9). Other species of the CTG clade (44) have two or three members of this protein family, whereas *S. cerevisiae* and *K. lactis* each possess only one Git homolog. Based on the robustly supported phylogenetic tree, homologs among *Candida* species can for the most part be grouped into one of four clades based on similarity to the *C. albicans* proteins (Fig. 9). The Git1 cluster appears to be evolutionarily stable, and the Git2/3/4 cluster more dynamic. Therefore, following the divergence of these two main clusters, there does not appear to be any subsequent gains or losses of genes among Git1 orthologs, although at least two additional gene duplications have occurred during the radiation of the *Candida* to create the Git2, Git3, and Git4 proteins likely followed by subsequent losses of genes. Interestingly, the phylogenetic



**FIGURE 9. Homologous proteins among Candida species form distinct Git clades.** Maximum likelihood tree of *C. albicans* (●) Git1 to Git4 proteins and homologs from related *Candida* species, along with additional Saccharomycetales including *S. cerevisiae* Git1 (▲). Bootstrap values from 10,000 replicates are given at nodes with greater than 50% support. The tree is drawn to scale, with branch lengths measured in a number of substitutions per site and rooted at the midpoint. Neighbor-joining methods produce trees with identical topology at all nodes (data not shown).

placement of the single proteins found in *S. cerevisiae* and *K. lactis*, along with the presence of a *Y. lipolytica* protein in both the Git1 and Git2/3/4 clusters, suggests that the gene duplication creating these two clusters may have occurred prior to the diversification of the Saccharomycetales and well before the whole genome duplication event in *Saccharomyces*. Although the biochemical activity, if any, of Git2 remains to be elucidated, it is worth noting that it is most similar in sequence to Git3 and that only the sister species *C. albicans* and *C. dubliniensis* retain all four paralogs.

## DISCUSSION

In this study, we have characterized multiple aspects of GroPCho transport and utilization in *C. albicans*, have identified several ways in which this metabolism differs from that which occurs in the nonpathogenic *S. cerevisiae* (Fig. 10), and have linked GroPCho transport to fungal pathogenicity. GroPCho is produced through the activity of deacylating phospholipases (Fig. 10C), such as those of the  $A_1$ -,  $A_2$ -, and B-type, that are widespread, having been found in bacteria (45, 46), fungi (7), and humans (47). Thus, GroPCho is a common metabolite, and its presence has been noted in several locations relevant to *C. albicans* infection, including serum (11, 12, 14–19), the gastrointestinal tract, and the urinary tract (11, 17, 19, 20).

Our work and that of others have shown that GroPXs are not dead-end metabolites but are recycled into biological molecules through some combination of transport and hydrolysis (Fig. 10) (22, 38, 39, 48–50). The ability of *C. albicans* to utilize GroPXs is expanded as compared with the nonpathogenic *S. cerevisiae* (22). *S. cerevisiae* has one transporter (ScGit1) whose preferred substrate is GroPIns. Furthermore, ScGit1 has only marginal GroPCho transport activity (Fig. 10B). In contrast, *C. albicans*




FIGURE 10. **Glycerophosphodiester transport and catabolism in *C. albicans* and *S. cerevisiae*.** *A*, in *C. albicans* Git1 acts as a GroPIIns transporter, whereas both Git3 and Git4 transport GroPCho. The host environment can provide GroPXs for utilization by the organism. The endogenous production of GroPXs by *C. albicans* has not been studied. *B*, in *S. cerevisiae* Git1 transports GroPIIns and has minor activity for GroPCho. Cell surface-associated PLBs are responsible for the production of extracellular GroPIIns and GroPCho. An endoplasmic reticulum-associated PLB, Nte1, is not shown. For both *A* and *B*, weight of arrows across transport proteins indicates relative transport activity. Catabolic products of GroPIIns and GroPCho as determined through radiolabeling studies are indicated. Question marks indicate that the gene product(s) involved are unknown. Dashed arrows indicate that inositol and choline are recycled back into membrane phospholipids. PM, plasma membrane. *C*, reaction illustrating deacylation of phosphatidylcholine to produce GroPCho and fatty acids. This reaction can be catalyzed by phospholipases of the A<sub>1</sub>-, A<sub>2</sub>-, or B-type.

has four ORFs with similarity to *ScGIT1* and much greater GroPCho transport activity (Fig. 10A) (22). Although we previously reported that Git1 transports GroPIIns (22), the data presented here indicate that Git3 and Git4 are GroPCho transporters. Evidence to support this conclusion is 2-fold as follows: (i) either Git3 or Git4 is required for early post-inoculation growth when GroPCho is supplied as sole phosphate source (Fig. 1A), and (ii) measurable transport of GroPCho requires either Git3 or Git4, with Git3 displaying much greater initial transport activity (Fig. 2, *A* and *B*). Although GroPCho transport has been described in *E. coli* (51, 52), and a GroPIIns permease (GLUT2) has been identified in mammalian cells (53), to the best of our knowledge this is the first identification of a GroPCho-specific permease in a eukaryotic organism.

At least three reasons exist for our inability to identify a role for Git2 in these studies. The first is that Git2 may transport a metabolite that was not tested, for example glycerophosphoserine or glycerophosphoethanolamine. The second is that *GIT2* was not sufficiently expressed under our experimental conditions. Although we did detect *GIT2* transcript by quantitative RT-PCR, as others have using RNA-seq (54), it was at a level roughly 6-fold less than that of *GIT3* under high phosphate (repressing) conditions (data not shown). Finally, Git2 may simply not act as a GroPX transporter or possess any other activity that would have been detected in this study.

Despite lacking a GroPCho transporter, a *git2,3,4Δ/Δ* mutant is able to initiate growth on GroPCho 12–18 h post-inoculation (Fig. 1A), suggesting that an alternative mechanism for GroPCho utilization is initiated in that time frame. Our data, obtained using [<sup>3</sup>H]GroPCho in which the choline molecule was labeled, indicate that this alternative mechanism involves the extracellular hydrolysis of [<sup>3</sup>H]GroPCho to [<sup>3</sup>H]choline and GroP, as we observe the production of extracellular [<sup>3</sup>H]choline

(Fig. 4D). Presumably, the unlabeled GroP is hydrolyzed to release free phosphate that is utilized by the cell. The hydrolysis of [<sup>3</sup>H]GroPCho into [<sup>3</sup>H]choline and GroP is the most likely pathway given that we did not detect [<sup>3</sup>H]choline-phosphate in internal or external fractions. It is worth noting that this transporter-independent pathway for GroPCho utilization does not exist in *S. cerevisiae*, where deletion of *ScGIT1* completely abolishes the ability of cells to utilize GroPCho as a phosphate source (39).

GroPXs are hydrolyzed to GroP and their respective alcohol by glycerophosphodiesterases (8, 55). To better understand GroPCho catabolism in *C. albicans*, we deleted *GDE1* (ORF 19.3936), which is predicted to be a cytosolic protein with a glycerophosphodiester phosphodiesterase domain. *Gde1* is highly similar to the only known GroPCho glycerophosphodiesterase in *S. cerevisiae* (*ScGde1*) and is annotated in CGD as a glycerophosphodiester glycerophosphodiesterase using InterPro (IPR004129) (56). Loss of *GDE1* resulted in a buildup of internal GroPCho (Figs. 3B and 7), providing evidence that *Gde1* acts upon internal GroPCho. The fact that we did not detect an increase in external GroPCho upon loss of *GDE1* (data not shown) and that *Gde1* does not contain a predicted signal peptide or GPI-anchor attachment site suggests that *Gde1* is not acting externally. Clearly, other gene products must exist that are capable of catabolizing GroPCho but are not highly similar to a standard glycerophosphodiesterase (IPR004129). This fact also stands in contrast to that which occurs in *S. cerevisiae*, where deletion of *ScGDE1* renders the cells unable to grow on GroPCho as a phosphate source (39).

As has been reported for plants (48, 49) and bacteria (50–52), we show here that GroPCho utilization in *C. albicans* is linked to phosphate limitation. *PHO4* and *GRF10* are orthologs to *ScPHO4* and *ScPHO2* (4), genes that encode transcription fac-



## GroPCho Transport and Utilization by *C. albicans*

tors that regulate phosphate-responsive genes in *S. cerevisiae* (40, 41). As was the case for *Git1* (22), the expression of *GIT3*, *GIT4*, and *GDE1* is governed by the transcriptional regulator *Pho4* (Fig. 5C). However, loss of *GRF10* does not affect the ability of *C. albicans* to utilize GroPCho (data not shown). Additionally, *GRF10* does not regulate the expression of *GIT1* (22), and others have noted that it does not appear to be involved in the phosphate response in *C. albicans* (21). Interestingly, a recent report indicates that phosphate limitation might have implications for *C. albicans* virulence (21). In this study, *C. albicans* strains isolated from the stool of critically ill patients underwent filamentation and expressed a lethal phenotype against mice and *C. elegans* upon phosphate limitation (21). It is tempting to speculate that the phosphate-regulated genes involved in utilization of GroPIns (*Git1*) (22) and GroPCho (*Git3*, *Git4*, and *Gde1*) may play a role in these phenotypes.

Besides acting as a nutrient source, other functions have been ascribed to GroPCho. A well known function involves osmotic regulation in renal medullary tissue of mammals, where GroPCho counteracts the effects of high NaCl and urea concentrations (12, 13). In the fungal pathogen, *Cryptococcus neoformans*, GroPCho appears to be required for capsule enlargement (57). Capsule enlargement is necessary for this organism's virulence, as it provides protection from phagocytosis as well as oxidation (57). A *C. neoformans* strain lacking phospholipase B1 (PLB1) loses its ability to enlarge its capsule, but supplementation of GroPCho rescues this phenotype (57). Interestingly, *C. neoformans* contains a putative protein that is 42% similar (NCBI-Blast) to *Git3* suggesting that it may also transport intact GroPCho.

We have shown previously that *C. albicans* is able to utilize GroPCho under conditions of elevated temperature and pH found in the human body (22). Here, we show that *C. albicans* employs *Git3* to transport and *Gde1* to metabolize GroPCho in the presence of serum and the concentration of phosphate found in serum, roughly 1 mM (Fig. 7). These results indicating that GroPCho transport and metabolism are physiological relevant functions under conditions of human infection, prompted us to perform mouse virulence studies on a strain lacking GroPCho transport capability. As shown in Fig. 8, a *git2,3,4Δ/Δ* mutant exhibits a virulence defect compared with the wild type strain, and reintegration of a single copy of *GIT3* into the *git2,3,4Δ/Δ* mutant restored wild type virulence levels. Thus, the major GroPCho transporter, *Git3*, is required for full virulence in a mouse model of blood stream infection. Of note, the phylogenetic tree of *Git* homologs (Fig. 9) suggests that several other *Candida* species with *Git3* and *Git4* orthologs may similarly possess GroPCho transport activity.

## REFERENCES

1. Fisher, J. F., Kavanagh, K., Sobel, J. D., Kauffman, C. A., and Newman, C. A. (2011) *Candida* urinary tract infection: pathogenesis. *Clin. Infect. Dis.* **52**, S437–S451
2. Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Jr., Calandra, T. F., Edwards, J. E., Jr., Filler, S. G., Fisher, J. F., Kullberg, B. J., Ostrosky-Zeichner, L., Reboli, A. C., Rex, J. H., Walsh, T. J., Sobel, J. D., and Infectious Diseases Society of America (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin. Infect. Dis.* **48**, 503–535
3. Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., and Edmond, M. B. (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin. Infect. Dis.* **39**, 309–317
4. Braun, B. R., van Het Hoog, M., d'Enfert, C., Martchenko, M., Dungan, J., Kuo, A., Inglis, D. O., Uhl, M. A., Hogues, H., Berriman, M., Lorenz, M., Levitin, A., Oberholzer, U., Bachewich, C., Hargus, D., Marcil, A., Dignard, D., Iouk, T., Zito, R., Frangeul, L., Tekai, F., Rutherford, K., Wang, E., Munro, C. A., Bates, S., Gow, N. A., Hoyer, L. L., Köhler, G., Morschhäuser, J., Newport, G., Znaidi, S., Raymond, M., Turcotte, B., Sherlock, G., Costanzo, M., Ihmels, J., Berman, J., Sanglard, D., Agabian, N., Mitchell, A. P., Johnson, A. D., Whiteway, M., and Nantel, A. (2005) A human-curated annotation of the *Candida albicans* genome. *PLoS Genet.* **1**, 36–57
5. Moran, G. P., Coleman, D. C., and Sullivan, D. J. (2011) Comparative genomics and the evolution of pathogenicity in human pathogenic fungi. *Eukaryot. Cell* **10**, 34–42
6. Ghannoum, M. A. (2000) Potential role of phospholipases in virulence and fungal pathogenesis. *Clin. Microbiol. Rev.* **13**, 122–143
7. Köhler, G. A., Brenot, A., Haas-Stapleton, E., Agabian, N., Deva, R., and Nigam, S. (2006) Phospholipase A<sub>2</sub> and phospholipase B activities in fungi. *Biochim. Biophys. Acta* **1761**, 1391–1399
8. Patton-Vogt, J. (2007) Transport and metabolism of glycerophosphodiesteres produced through phospholipid deacylation. *Biochim. Biophys. Acta* **1771**, 337–342
9. Leidich, S. D., Ibrahim, A. S., Fu, Y., Koul, A., Jessup, C., Vitullo, J., Fonzi, W., Mirbod, F., Nakashima, S., Nozawa, Y., and Ghannoum, M. A. (1998) Cloning and disruption of *caPLB1*, a phospholipase B gene involved in the pathogenicity of *Candida albicans*. *J. Biol. Chem.* **273**, 26078–26086
10. Theiss, S., Ishdorj, G., Brenot, A., Kretschmar, M., Lan, C. Y., Nichterlein, T., Hacker, J., Nigam, S., Agabian, N., and Köhler, G. A. (2006) Inactivation of the phospholipase B gene *PLB5* in wild type *Candida albicans* reduces cell-associated phospholipase A<sub>2</sub> activity and attenuates virulence. *Int. J. Med. Microbiol.* **296**, 405–420
11. Backshall, A., Alferez, D., Teichert, F., Wilson, I. D., Wilkinson, R. W., Goodlad, R. A., and Keun, H. C. (2009) Detection of metabolic alterations in non-tumor gastrointestinal tissue of the *Apc(Min+)* mouse by <sup>1</sup>H MAS NMR spectroscopy. *J. Proteome Res.* **8**, 1423–1430
12. Gallazzini, M., and Burg, M. B. (2009) What's new about osmotic regulation of glycerophosphocholine. *Physiology* **24**, 245–249
13. Gallazzini, M., Ferraris, J. D., and Burg, M. B. (2008) GPPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 11026–11031
14. Icol, Y. O., Ozbek, R., Hamurtekin, E., and Ulus, I. H. (2005) Choline status in newborns, infants, children, breast-feeding women, breast-fed infants and human breast milk. *J. Nutr. Biochem.* **16**, 489–499
15. Klein, J., Gonzalez, R., Köppen, A., and Löffelholz, K. (1993) Free choline and choline metabolites in rat brain and body fluids: sensitive determination and implications for choline supply to the brain. *Neurochem. Int.* **22**, 293–300
16. Paban, V., Fauvelle, F., and Alescio-Lautier, B. (2010) Age-related changes in metabolic profiles of rat hippocampus and cortices. *Eur. J. Neurosci.* **31**, 1063–1073
17. Senar, S., Recio, M. N., and Pérez-Albarsanz, M. A. (1994) Lindane affects phosphoinositide turnover through a different mechanism of the phosphatidylinositol synthesis inhibition in rat renal proximal tubule cell culture. *Cell. Signal.* **6**, 433–438
18. Walter, A., Korth, U., Hilgert, M., Hartmann, J., Weichel, O., Hilgert, M., Fassbender, K., Schmitt, A., and Klein, J. (2004) Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. *Neurobiol. Aging* **25**, 1299–1303
19. Wang, Y., Holmes, E., Comelli, E. M., Fotopoulos, G., Dorta, G., Tang, H., Rantalainen, M. J., Lindon, J. C., Corthésy-Theulaz, I. E., Fay, L. B., Kochhar, S., and Nicholson, J. K. (2007) Topographical variation in metabolic signatures of human gastrointestinal biopsies revealed by high-resolution

- magic-angle spinning  $^1\text{H}$  NMR spectroscopy. *J. Proteome Res.* **6**, 3944–3951
20. Wang, Y., Tang, H., Holmes, E., Lindon, J. C., Turini, M. E., Sprenger, N., Bergonzelli, G., Fay, L. B., Kochhar, S., and Nicholson, J. K. (2005) Biochemical characterization of rat intestine development using high-resolution magic-angle-spinning  $^1\text{H}$  NMR spectroscopy and multivariate data analysis. *J. Proteome Res.* **4**, 1324–1329
  21. Romanowski, K., Zaborin, A., Valuckaite, V., Rolfes, R. J., Babrowski, T., Bethel, C., Olivas, A., Zaborina, O., and Alverdy, J. C. (2012) *Candida albicans* isolates from the gut of critically ill patients respond to phosphate limitation by expressing filaments and a lethal phenotype. *PLoS One* **7**, 1–11
  22. Bishop, A. C., Sun, T., Johnson, M. E., Bruno, V. M., and Patton-Vogt, J. (2011) Robust utilization of phospholipase-generated metabolites, glycerophosphodiester, by *Candida albicans*: role of the CaGit1 permease. *Eukaryot. Cell* **10**, 1618–1627
  23. Gaur, M., Puri, N., Manoharlal, R., Rai, V., Mukhopadhyay, G., Choudhury, D., and Prasad, R. (2008) MFS transportome of the human pathogenic yeast *Candida albicans*. *BMC Genomics* **9**, 579
  24. Patton, J. L., Pessoa-Brandao, L., and Henry, S. A. (1995) Production and reutilization of an extracellular phosphatidylinositol catabolite, glycerophosphoinositol, by *Saccharomyces cerevisiae*. *J. Bacteriol.* **177**, 3379–3385
  25. Ganguly, S., and Mitchell, A. P. (2012) Mini-blaster-mediated targeted gene disruption and marker complementation in *Candida albicans*. *Methods Mol. Biol.* **845**, 19–39
  26. Wilson, R. B., Davis, D., Enloe, B. M., and Mitchell, A. P. (2000) A recyclable *Candida albicans* URA3 cassette for PCR product-directed gene disruptions. *Yeast* **16**, 65–70
  27. Hama, H., Takemoto, J. Y., and DeWald, D. B. (2000) Analysis of phosphoinositides in protein trafficking. *Methods* **20**, 465–473
  28. Hanes, C. S. (1932) Studies on plant amylases: The effect of starch concentration upon the velocity of hydrolysis by the amylase of germinated barley. *Biochem. J.* **26**, 1406–1421
  29. Dowd, S. R., Bier, M. E., and Patton-Vogt, J. L. (2001) Turnover of phosphatidylcholine in *Saccharomyces cerevisiae*. The role of the CDP-choline pathway. *J. Biol. Chem.* **276**, 3756–3763
  30. Cook, S. J., and Wakelam, M. J. (1989) Analysis of the water-soluble products of phosphatidylcholine breakdown by ion-exchange chromatography. Bombesin and TPA (12-*O*-tetradecanoylphorbol 13-acetate) stimulate choline generation in Swiss 3T3 cells by a common mechanism. *Biochem. J.* **263**, 581–587
  31. Elion, E. A., and Warner, J. R. (1984) The major promoter element of rRNA transcription in yeast lies 2 kb upstream. *Cell* **39**, 663–673
  32. Pfaffl, M. W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.* **29**, e45
  33. Taff, H. T., Nett, J. E., and Andes, D. R. (2012) Comparative analysis of *Candida* biofilm quantitation assays. *Med. Mycol.* **50**, 214–218
  34. Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R., Thompson, J. D., Gibson, T. J., and Higgins, D. G. (2007) Clustal W and Clustal X version 2.0. *Bioinformatics* **23**, 2947–2948
  35. Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., and Kumar, S. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol. Biol. Evol.* **28**, 2731–2739
  36. Johnson, M., Zaretskaya, I., Raytselis, Y., Merezukh, Y., McGinnis, S., and Madden, T. L. (2008) NCBI BLAST: a better web interface. *Nucleic Acids Res.* **36**, W5–W9
  37. Almaguer, C., Cheng, W., Nolder, C., and Patton-Vogt, J. (2004) Glycerophosphoinositol, a novel phosphate source whose transport is regulated by multiple factors in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **279**, 31937–31942
  38. Fernández-Murray, J. P., and McMaster, C. R. (2005) Glycerophosphocholine catabolism as a new route for choline formation for phosphatidylcholine synthesis by the Kennedy pathway. *J. Biol. Chem.* **280**, 38290–38296
  39. Fisher, E., Almaguer, C., Holic, R., Griac, P., and Patton-Vogt, J. (2005) Glycerophosphocholine-dependent growth requires Gde1p (YPL110c) and Git1p in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **280**, 36110–36117
  40. Mouillon, J. M., and Persson, B. L. (2006) New aspects on phosphate sensing and signalling in *Saccharomyces cerevisiae*. *FEMS Yeast Res.* **6**, 171–176
  41. Persson, B. L., Lagerstedt, J. O., Pratt, J. R., Pattison-Granberg, J., Lundh, K., Shokrollahzadeh, S., and Lundh, F. (2003) Regulation of phosphate acquisition in *Saccharomyces cerevisiae*. *Curr. Genet.* **43**, 225–244
  42. Heimburger, D. C., Koethe, J. R., Nyirenda, C., Bosire, C., Chiasera, J. M., Blevins, M., Munoz, A. J., Shepherd, B. E., Potter, D., Zulu, I., Chisembe-Taylor, A., Chi, B. H., Stringer, J. S., and Kabagambe, E. K. (2010) Serum phosphate predicts early mortality in adults starting antiretroviral therapy in Lusaka, Zambia: a prospective cohort study. *PLoS One* **5**, e10687
  43. Ghosh, S., Sengupta, A., Sharma, S., and Sonawat, H. M. (2012) Metabolic fingerprints of serum, brain, and liver are distinct for mice with cerebral and noncerebral malaria: a  $^1\text{H}$  NMR spectroscopy-based metabolomic study. *J. Proteome Res.* **11**, 4992–5004
  44. Santos, M. A., Ueda, T., Watanabe, K., and Tuite, M. F. (1997) The non-standard genetic code of *Candida* spp.: an evolving genetic code or a novel mechanism for adaptation? *Mol. Microbiol.* **26**, 423–431
  45. Farn, J. L., Strugnell, R. A., Hoyne, P. A., Michalski, W. P., and Tennent, J. M. (2001) Molecular characterization of a secreted enzyme with phospholipase B activity from *Moraxella bovis*. *J. Bacteriol.* **183**, 6717–6720
  46. Jiang, F., Huang, S., Imadad, K., and Li, C. (2012) Cloning and expression of a gene with phospholipase B activity from *Pseudomonas fluorescens* in *Escherichia coli*. *Bioresour. Technol.* **104**, 518–522
  47. Xu, S., Zhao, L., Larsson, A., and Venge, P. (2009) The identification of a phospholipase B precursor in human neutrophils. *FEBS J.* **276**, 175–186
  48. Cheng, L., Bucciarelli, B., Liu, J., Zinn, K., Müller, S., Patton-Vogt, J., Allan, D., Shen, J., and Vance, C. P. (2011) White lupin cluster root acclimation to phosphorus deficiency and root hair development involve unique glycerophosphodiester phosphodiesterases. *Plant Physiol.* **156**, 1131–1148
  49. Cheng, Y., Zhou, W., El Sheery, N. I., Peters, C., Li, M., Wang, X., and Huang, J. (2011) Characterization of the *Arabidopsis* glycerophosphodiester phosphodiesterase (GDPD) family reveals a role of the plastid-localized AtGDPD1 in maintaining cellular phosphate homeostasis under phosphate starvation. *Plant J.* **66**, 781–795
  50. Ohshima, N., Yamashita, S., Takahashi, N., Kuroishi, C., Shiro, Y., and Takio, K. (2008) *Escherichia coli* cytosolic glycerophosphodiester phosphodiesterase (UgpQ) requires  $\text{Mg}^{2+}$ ,  $\text{Co}^{2+}$ , or  $\text{Mn}^{2+}$  for its enzyme activity. *J. Bacteriol.* **190**, 1219–1223
  51. Brzoska, P., and Boos, W. (1988) Characteristics of a ugp-encoded and phoB-dependent glycerophosphoryl diester phosphodiesterase which is physically dependent on the ugp transport system of *Escherichia coli*. *J. Bacteriol.* **170**, 4125–4135
  52. Overduin, P., Boos, W., and Tommassen, J. (1988) Nucleotide sequence of the ugp genes of *Escherichia coli* K-12: homology to the maltose system. *Mol. Microbiol.* **2**, 767–775
  53. Mariggio, S., Iurisci, C., Sebastia, J., Patton-Vogt, J., and Corda, D. (2006) Molecular characterization of a glycerophosphoinositol transporter in mammalian cells. *FEBS Lett.* **580**, 6789–6796
  54. Bruno, V. M., Wang, Z., Marjani, S. L., Euskirchen, G. M., Martin, J., Sherlock, G., and Snyder, M. (2010) Comprehensive annotation of the transcriptome of the human fungal pathogen *Candida albicans* using RNA-seq. *Genome Res.* **20**, 1451–1458
  55. Yanaka, N. (2007) Mammalian glycerophosphodiester phosphodiesterases. *Biosci. Biotechnol. Biochem.* **71**, 1811–1818
  56. Hunter, S., Jones, P., Mitchell, A., Apweiler, R., Attwood, T. K., Bateman, A., Bernard, T., Binns, D., Bork, P., Burge, S., de Castro, E., Coghill, P., Corbett, M., Das, U., Daugherty, L., Duquenne, L., Finn, R. D., Fraser, M., Gough, J., Haft, D., Hulo, N., Kahn, D., Kelly, E., Letunic, I., Lonsdale, D., Lopez, R., Madera, M., Maslen, J., McAnulla, C., McDowall, J., McMenamin, C., Mi, H., Mutowo-Muellenet, P., Mulder, N., Natale, D., Orengo, C., Pesseat, S., Punta, M., Quinn, A. F., Rivoire, C., Sangrador-Vegas, A., Selengut, J. D., Sigrist, C. J., Scheremetjew, M., Tate, J., Thimmajananathan, M., Thomas, P. D., Wu, C. H., Yeats, C., and Yong, S. Y. (2012) InterPro in 2011: new developments in the family and domain

## GroPCho Transport and Utilization by *C. albicans*

- prediction database. *Nucleic Acids Res.* **40**, D306–D312
57. Chrisman, C. J., Albuquerque, P., Guimaraes, A. J., Nieves, E., and Casadevall, A. (2011) Phospholipids trigger *Cryptococcus neoformans* capsular enlargement during interactions with amoebae and macrophages. *PLoS Pathog.* **7**, e1002047
58. Davis, D. A., Bruno, V. M., Loza, L., Filler, S. G., and Mitchell, A. P. (2002) *Candida albicans* Mds3p, a conserved regulator of pH responses and virulence identified through insertional mutagenesis. *Genetics* **162**, 1573–1581
59. Homann, O. R., Dea, J., Noble, S. M., and Johnson, A. D. (2009) A phenotypic profile of the *Candida albicans* regulatory network. *PLoS Genet.* **5**, e1000783